Article
BioMarin gets its dwarfism drug in the FDA's door — but can they change regulators' minds about
Rating:
0.0
Views:
114
Likes:
1
Library:
1
BioMarin's dwarfism drug has secured a place in the FDA's review line, but disagreements with regulators on just how long the follow-up period should be are threatening to put the biotech in an uneasy position. We'll
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value